Strategies Towards Personalised Treatment in Juvenile Idiopathic Arthritis (JIA).

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

189 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-01

Study Completion Date

2025-02-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Inhibitors of tumour necrosis factor (TNFa) reduce inflammation in patients with juvenile idiopathic arthritis (JIA), but only 20-40 percent achieve a state of no or very little disease activity. Tailored glucocorticoid joint injections are widely used (usually in general anaesthesia), but no controlled studies have addressed the effect of this approach. In Norway there are unique possibilities for early interventions, rapid escalation of medication and individualised therapy. The investigators aim to find the optimal ways to increase disease control and improve quality of life for JIA patients.

The hypothesis is that JIA patients starting TNF-inhibitors with added steroid injection of inflamed joints, will lead to improved outcomes compared to TNF-inhibitors with no joint injections, and that therapeutic drug monitoring, modern imaging and biologic and clinical profiling can be utilised to characterise JIA patients with different anti-TNF responses.

MyJIA is a national investigator initiated 48 weeks RCT of JIA patients starting TNF-inhibitors; 202 JIA patients will be randomised at baseline to A) concomitant intra-articular glucocorticoid injections versus B) no injections. Primary endpoint is the rate of sustained remission from weeks 24 to 36. Possible risk factors for not reaching remission will be analysed including clinical characteristics, drug antibodies/serum concentrations, patients' reported health status and preferences, molecular signalling (based on transcriptional, cellular and genetic risk) and synovitis detected by modern imaging (ultrasound and whole-body MRI).

Patients will be recruited from all Norwegian health regions through an established collaboration. Unit of Paediatric Rheumatology, Oslo University Hospital, with an extensive research track in this field, will be the coordinating centre. Broad research cooperation across disciplines is established. The trial is highly innovative in evaluating treatment options and strategies to individualise and optimise the efficacy and safety of JIA treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema

NCT01832896

Hereditary Angioedema Types I and II

WITHDRAWN PHASE2

Juvenile Inflammatory Rheumatism (JIR) Cohorte

NCT02377245

Arthritis, Juvenile Rheumatoid

ENROLLING_BY_INVITATION

Infliximab to Treat Children With Juvenile Rheumatoid Arthritis

NCT00029042

Juvenile Rheumatoid Arthritis

TERMINATED PHASE2

Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

NCT01803321

Systemic Juvenile Idiopathic Arthritis

COMPLETED PHASE1

Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)

NCT05194540

Atopic Dermatitis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Juvenile Idiopathic Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Parallel intervention were participants are assigned to either the control group or intervention group.

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

The individual who evaluates joints clinically will be blinded to study information.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention

Intra-articular corticosteroid injections into active joints

Group Type ACTIVE_COMPARATOR

Triamcinolone Hexacetonide 20 MG/ML

Intervention Type DRUG

JIA patients (age 1-18 years) starting TNFi treatment randomised to intervention will receive treatment with intra articular glucocorticoids (triamcinolone hexacetonide) injections in inflamed joints

Comparator

No intra-articular injections

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Triamcinolone Hexacetonide 20 MG/ML

JIA patients (age 1-18 years) starting TNFi treatment randomised to intervention will receive treatment with intra articular glucocorticoids (triamcinolone hexacetonide) injections in inflamed joints

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lederspan

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 1-18 years of age at the time of signing the informed consent.
2. Fulfilment of the International League of Associations for Rheumatology (ILAR) classification criteria for non-systemic JIA.
3. Clinical indication for starting TNFi treatment according to consensus between at least two physicians.
4. Naïve to TNFi or prior use of one TNFi (stopped at least 3 months before study inclusion and no previous TNFi treatment failure).
5. Juvenile Disease Activity Score (JADAS) \>1 at baseline and at least one joint with active arthritis were joint injection is considered.
6. Willing to give written consent (participant ≥ 16, guardians if \< 16 years of age, both participants and guardians if 16-18) and comply with the requirements of the study protocol.

Exclusion Criteria

Medical Conditions

1. Major comorbidity including uncontrolled infectious, neurological or mental disease, malignant disease, severe heart failure, severe renal failure, active ulcus ventriculi, and uncontrolled diabetes mellitus.

Prior/Concomitant Therapy
2. Used two or more TNFi.
3. Corticosteroid use (including i.a. injection) less than 4 weeks prior to randomisation.

Other Exclusions
4. Known hypersensitivity to Triamcinolone hexacetonide (Lederspan) or any of the excipients (sorbitol, polysorbate or benzyl alcohol).
5. Concomitant therapy with CYP3A-inhibitors or digitalis glycosides.
6. Known inherited fructose intolerance
7. Presence of hepatitis B surface antigen (HBsAg) at screening.
8. Positive hepatitis C antibody test result at screening or within 12 months prior to starting study treatment.
9. Evidence of active or latent tuberculosis (TB) as documented by medical history and examination, chest X-rays (front), and TB testing. The choice of TB tests will be made by the investigator according to local licensing and standard of care.
10. Having received live vaccines less than two weeks prior to randomisation.
11. Drug / alcohol abuse which hampers adherence to the study protocol.
12. Language barriers that hampers adherence to the study protocol.
13. Pregnancy or breast-feeding.

Minimum Eligible Age

1 Year

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No